Philadelphia-based chemical manufacturing company FMC Corporation outlined its priorities for 2026 and plans to explore strategic options.
Among its 2026 priorities, FMC is focused on strengthening its balance sheet by paying down $1 billion in debt through asset sales and licensing agreements. This includes the previously announced sale of the India commercial business.
Other priorities focus on improving the competitiveness of the company’s core portfolio and managing the post-patent transition for Rynaxypyr active. In addition, FMC will continue advancing commercialization of new active ingredients, including Isoflex active, fluindapyr, Dodhylex active and rimisoxafen.
In addition, the company announced that it will explore its strategic options related to its four new active ingredients, along with its broader development pipeline. The company believes there is significant opportunity to accelerate growth and deliver enhanced financial results with additional investment in these technologies.
“Our focus in 2026 is on executing our operational priorities, which include strengthening the balance sheet and improving the overall competitiveness of our portfolio,” Pierre Brondeau, chairman, CEO, and president, said. “In parallel, the Board has authorized the exploration of strategic options to maximize shareholder value and to help ensure our valuable assets and pipeline are positioned for long-term success.”
Officials note that the strategic review is at a preliminary stage and there is no assurance that the process will result in any transaction.
FMC also released its earnings for the full fiscal year. In 2025, FMC reported revenue of $3.47 billion, a decrease of 18 percent compared to 2024. The company reported a full-year net loss of $2.24 billion, down $2.58 billion versus the previous year.
For the fourth quarter, FMC reported revenue of $1.08 billion, a decline of 12 percent versus fourth quarter 2024. It had a net loss was $1.72 billion.